Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
TScan Therapeutics develops T cell receptor (TCR)-engineered T cell therapies targeting cancer. Its platform identifies clinically relevant TCRs from patients with exceptional responses, enabling personalized and multiplexed treatments for hematologic malignancies and solid tumors. The company focuses on creating scalable manufacturing processes, expanding its TCR bank, and advancing clinical trials to deliver innovative immunotherapies that address tumor heterogeneity and resistance.
This description was generated via AI from an annual report. Updated about 1 year ago.